{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:01Z","timestamp":1781650801925,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myeloid\/lymphoid neoplasms with eosinophilia (MLN-eo) associated with\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    rearrangements represent a rare but clinically significant category of hematologic malignancies, characterized by clonal eosinophilia and exceptional sensitivity to tyrosine kinase inhibitors. Among these, the\n                    <jats:italic>MPRIP<\/jats:italic>\n                    ::\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    fusion is exceptionally uncommon, with only three patients previously reported. Here, we report the first United States patient with\n                    <jats:italic>MPRIP<\/jats:italic>\n                    ::\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    fusion in a 34-year-old man presenting with leukocytosis, marked eosinophilia, anemia, thrombocytopenia, mucocutaneous lesions, hepatosplenomegaly, chronic gastrointestinal symptoms, and tree-in-bud pulmonary nodularity. Bone marrow evaluation revealed a markedly hypercellular marrow with increased eosinophils, grade 1 reticulin fibrosis, and dysmegakaryopoiesis. Fluorescence in situ hybridization (FISH) demonstrated a\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    rearrangement in 76% of cells, and chromosome analysis revealed a balanced translocation t(5;17)(q32;p11.2). Next-generation sequencing RNA-based myeloid fusion panel analysis identified an\n                    <jats:italic>MPRIP<\/jats:italic>\n                    ::\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    fusion formed by an in-frame junction of\n                    <jats:italic>MPRIP<\/jats:italic>\n                    exon 20 and\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    exon 12. The patient was initiated on imatinib therapy and achieved rapid remission. To contextualize this patient, we compared the clinical and molecular features of all previously published patients with\n                    <jats:italic>MPRIP<\/jats:italic>\n                    ::\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    fusion, noting shared findings of marked eosinophilia and excellent imatinib sensitivity, but notable heterogeneity in symptom burden, degree of marrow fibrosis, and associated immune-related manifestations. Additionally, we provide an overview of 45 reported\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    fusion partner genes, summarizing their cytogenetic characteristics, and associated diseases. This case report expands the clinical spectrum of\n                    <jats:italic>MPRIP<\/jats:italic>\n                    ::\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    positive MLN-eo and underscores the essential role of cytogenetic and molecular testing in the diagnostic evaluation of eosinophilia, given the significant therapeutic implications of identifying\n                    <jats:italic>PDGFRB<\/jats:italic>\n                    fusions.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07035-8","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:18:40Z","timestamp":1777263520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MPRIP::PDGFRB fusion identified in a male patient with a myeloid\/lymphoid neoplasm with eosinophilia"],"prefix":"10.1007","volume":"105","author":[{"given":"Min","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimo","family":"Bachiashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Craig","family":"Mackinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Ravindran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady M.","family":"Mikhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"1","key":"7035_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.26352","volume":"97","author":"W Shomali","year":"2022","unstructured":"Shomali W, Gotlib J (2022) World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(1):129\u2013148","journal-title":"Am J Hematol"},{"issue":"6","key":"7035_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","volume":"129","author":"A Reiter","year":"2017","unstructured":"Reiter A, Gotlib J (2017) Myeloid neoplasms with eosinophilia. Blood 129(6):704\u2013714","journal-title":"Blood"},{"issue":"3","key":"7035_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/ajcp\/aqaa056","volume":"154","author":"DM Mattis","year":"2020","unstructured":"Mattis DM, Wang SA, Lu CM (2020) Contemporary classification and diagnostic evaluation of hypereosinophilia. Am J Clin Pathol 154(3):305\u2013318","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"7035_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/his.15021","volume":"83","author":"L Saft","year":"2023","unstructured":"Saft L, Kvasnicka HM, Boudova L, Gianelli U, Lazzi S, Rozman M (2023) Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases. Histopathology 83(6):829\u2013849","journal-title":"Histopathology"},{"issue":"12","key":"7035_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/gcc.22287","volume":"54","author":"N Naumann","year":"2015","unstructured":"Naumann N, Schwaab J, Metzgeroth G, Jawhar M, Haferlach C, Gohring G et al (2015) Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. Genes Chromosomes Cancer 54(12):762\u2013770","journal-title":"Genes Chromosomes Cancer"},{"key":"7035_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cancergen.2017.03.004","volume":"212\u2013213","author":"YS Zou","year":"2017","unstructured":"Zou YS, Hoppman NL, Singh ZN, Sawhney S, Kotiah SD, Baer MR (2017) Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. Cancer Genet 212\u2013213:38\u201344","journal-title":"Cancer Genet"},{"issue":"2","key":"7035_CR7","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.3324\/haematol.2017.165282","volume":"103","author":"MS Zabriskie","year":"2018","unstructured":"Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD et al (2018) A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica 103(2):e87\u2013e91","journal-title":"Haematologica"},{"key":"7035_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-019-0136-y","volume":"8","author":"I Panagopoulos","year":"2019","unstructured":"Panagopoulos I, Brunetti M, Stoltenberg M, Strandab\u00f8 RAU, Staurseth J, Andersen K et al (2019) Novel GTF2I-PDGFRB and IKZF1-TYW1 fusions in pediatric leukemia with normal karyotype. Exp Hematol Oncol 8:12","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"7035_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.4143\/crt.2020.1272","volume":"53","author":"X Xu","year":"2021","unstructured":"Xu X, Lu Q, Wang Z, Cai P, Zeng Z, Zhang L et al (2021) Identification of a novel CSNK2A1-PDGFRB fusion gene in a patient with myeloid neoplasm with eosinophilia. Cancer Res Treat 53(3):889\u2013892","journal-title":"Cancer Res Treat"},{"issue":"10","key":"7035_CR10","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00277-022-04902-y","volume":"101","author":"T Wang","year":"2022","unstructured":"Wang T, Cao J, Lin Q, Liu X, Wang M, Pei R et al (2022) A novel WNK1::PDGFRB fusion gene in myeloid neoplasm with eosinophilia: a case report. Ann Hematol 101(10):2359\u20132361","journal-title":"Ann Hematol"},{"issue":"1","key":"7035_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41698-023-00485-7","volume":"7","author":"B Miyazaki","year":"2023","unstructured":"Miyazaki B, Ueno T, Sugiyama M, Kojima S, Arakawa A, Tao K et al (2023) Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia. NPJ Precis Oncol 7(1):132","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"7035_CR12","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41375-023-01843-x","volume":"37","author":"T Sadras","year":"2023","unstructured":"Sadras T, Jalud FB, Kosasih HJ, Horne CR, Brown LM, El-Kamand S et al (2023) Unusual PDGFRB fusion reveals novel mechanism of kinase activation in Ph-like B-ALL. Leukemia 37(4):905\u2013909","journal-title":"Leukemia"},{"issue":"1","key":"7035_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-023-00380-8","volume":"12","author":"X Zhang","year":"2023","unstructured":"Zhang X, Hou Z, Huang D, Wang F, Gao B, Zhang C et al (2023) Single-cell heterogeneity and dynamic evolution of Ph-like acute lymphoblastic leukemia patient with novel TPR-PDGFRB fusion gene. Exp Hematol Oncol 12(1):19","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"7035_CR14","doi-asserted-by":"publisher","first-page":"e18114","DOI":"10.1111\/jcmm.18114","volume":"28","author":"GF Xu","year":"2024","unstructured":"Xu GF, Zeng Z, Zhang ZB, Zhang XM, Wang M, Xiao Q et al (2024) The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB\/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL. J Cell Mol Med 28(3):e18114","journal-title":"J Cell Mol Med"},{"issue":"10","key":"7035_CR15","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1007\/s00277-025-06620-7","volume":"104","author":"F Ye","year":"2025","unstructured":"Ye F, Wang L, Qian Y, Deng W, Yu Y, Yang L (2025) Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy. Ann Hematol 104(10):5507\u20135512","journal-title":"Ann Hematol"},{"issue":"5","key":"7035_CR16","first-page":"1373","volume":"109","author":"S De Coninck","year":"2024","unstructured":"De Coninck S, De Smedt R, Lintermans B, Reunes L, Kosasih HJ, Reekmans A et al (2024) Targeting hyperactive platelet-derived growth factor receptor-\u03b2 signaling in T-cell acute lymphoblastic leukemia and lymphoma. Haematologica 109(5):1373\u20131384","journal-title":"Haematologica"},{"issue":"1","key":"7035_CR17","doi-asserted-by":"publisher","first-page":"e70028","DOI":"10.1002\/gcc.70028","volume":"64","author":"F Boccia","year":"2025","unstructured":"Boccia F, Barresi S, Vallese S, Martino VD, Bombaci S, Massuras S et al (2025) Novel PDGFRB gene fusions in two cases of infantile myofibromatosis. Genes Chromosomes Cancer 64(1):e70028","journal-title":"Genes Chromosomes Cancer"},{"issue":"52","key":"7035_CR18","doi-asserted-by":"publisher","first-page":"42543","DOI":"10.1074\/jbc.M506863200","volume":"280","author":"HK Surks","year":"2005","unstructured":"Surks HK, Riddick N, Ohtani K (2005) M-RIP targets myosin phosphatase to stress fibers to regulate myosin light chain phosphorylation in vascular smooth muscle cells. J Biol Chem 280(52):42543\u201342551","journal-title":"J Biol Chem"},{"key":"7035_CR19","doi-asserted-by":"publisher","first-page":"10387","DOI":"10.2147\/OTT.S270961","volume":"13","author":"Y Shu","year":"2020","unstructured":"Shu Y, Li H, Shang H, Chen J, Su X, Le W et al (2020) Identification of a novel MPRIP-ROS1 fusion and clinical efficacy of crizotinib in an advanced lung adenocarcinoma patient: A Case Report. Onco Targets Ther 13:10387\u201310391","journal-title":"Onco Targets Ther"},{"issue":"3","key":"7035_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5430\/dcc.v8n3p1","volume":"8","author":"K Beel","year":"2021","unstructured":"Beel K, Ameye G, Kelver W, Michaux L (2021) Case report: MPN-eo with balanced rearrangement of MPRIP-PDGFRB t (5; 17)(q32; p11), responding to low dose imatinib. Discussion Clin Cases 8(3):1","journal-title":"Discussion Clin Cases"},{"key":"7035_CR21","first-page":"7098722","volume":"2025","author":"T Ukkahad","year":"2025","unstructured":"Ukkahad T, Thamgrang T (2025) MPRIP::PDGFRB fusion gene: A rare case report of adult myeloid\/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions. Case Rep Hematol 2025:7098722","journal-title":"Case Rep Hematol"},{"issue":"4","key":"7035_CR22","doi-asserted-by":"publisher","first-page":"e63951","DOI":"10.1002\/ajmg.a.63951","volume":"197","author":"M Gao","year":"2025","unstructured":"Gao M, Chen Y, Lertwilaiwittaya P, Hurst AC, Al-Beshri A, Carroll AJ et al (2025) Constitutional mosaic pericentromeric trisomy 8 in a female patient with aplastic anemia. Am J Med Genet Part A 197(4):e63951","journal-title":"Am J Med Genet Part A"},{"issue":"1","key":"7035_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S et al (2017) Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and college of american pathologists. J Mol Diagn 19(1):4\u201323","journal-title":"J Mol Diagn"},{"issue":"2","key":"7035_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","volume":"77","author":"TR Golub","year":"1994","unstructured":"Golub TR, Barker GF, Lovett M, Gilliland DG (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77(2):307\u2013316","journal-title":"Cell"},{"issue":"2","key":"7035_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.10980","volume":"92","author":"C Walz","year":"2007","unstructured":"Walz C, Metzgeroth G, Haferlach C, Schmitt-Graeff A, Fabarius A, Hagen V et al (2007) Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 92(2):163\u2013169","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07035-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:46:29Z","timestamp":1781649989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07035-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7035"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07035-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted under a University of Alabama at Birmingham (UAB) Institutional Review Boar-approved protocol (IRB-130710002), titled \u201cCytogenetics Laboratory Patients Phenotype Information Database.\u201d The protocol allows for the collection and research use of phenotypic information from patients evaluated in the UAB Clinical Cytogenetics Laboratory who were found to have abnormalities through clinical testing. All data included in this report were collected in accordance with institutional ethical standards, and the phenotypic information was used for research purposes, including publication, as permitted by the protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The patient provided written informed consent for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}